Advertisement
For healthcare professionals only
Introduction
Iron deficiency has a major impact on cellular function, which is important in patients with heart failure with reduced ejection fraction because the prevalence is high. Interestingly, iron deficiency is not synonymous with anaemia – 50–73% of heart failure (HF) patients are iron deficient, yet 46% are not anaemic.1 The familiar response to treatment with iron, an increase in haemoglobin, does not always occur with iron treatment in patients with heart failure, yet replenishment does improve mitrochondrial function. It is notable that iron-containing proteins have a vital role in cellular energy metabolism. Remarkably, very few (1.5%) HF patients actually undergo assessment of iron status.1 Clearly, absolute iron deficiency mandates appropriate investigations to determine the underlying cause.
History of iron from oral to intravenous
Oral iron supplementation is immediately attractive to clinicians, it is easy to administer and cheap, although it causes gastrointestinal perturbation such as thick green tenacious stool, which often results in poor adherence. Could oral iron administration be efficacious in the setting of heart failure with reduced ejection fraction (HFrEF) where hepcidin, the main regulator of iron uptake and release, is increased, potentially limiting the uptake of oral iron (figure 1)?2
There are very few studies investigating oral iron therapy in patients with HF and iron deficiency. The efficacy of oral iron administration in HFrEF was explored in the IRONOUT study, which sought to determine whether administration improved maximal oxygen uptake capacity in patients with HFrEF and iron deficiency.3 The form of oral iron used in this study was iron polysaccharide, which is not a form of iron available in the UK. Participants were randomised to oral iron for 16 weeks or placebo. The study found no benefit from oral iron on exercise capacity in any subgroup.4,5
The purpose of iron supplementation is to replenish low iron stores. Analysis of the IRONOUT study was salutary, the effect of iron polysaccharide administered orally was disappointing. The transferrin saturations (TS) increased by only 3% and ferritin by 11 ng/ml after 16 weeks. However, the duration of the study was relatively short, additionally, iron polysaccharide, is not a commonly used preparation and is not universally available.
Intravenous (IV) iron in the form of ferric carboxymaltose was used in the CONFIRM-HF study: TS increased by 5.7%, ferritin by 200 ng/ml, yet haemoglobin by only 1 g/dL at one year. While the latter may appear disappointing, it should be remembered that iron is present in a wide range of cells beyond haemoglobin, and iron infusions are associated with improved mitochondrial function, including those in myocytes, in heart failure patients.6 Furthermore, exercise intolerance in patients with HFrEF and iron deficiency is likely to be independent of haemoglobin. A single infusion of iron can result in changes compatible with several weeks of exercise training.
Role of intravenous iron
Disappointing results with oral iron and early studies with IV iron reporting beneficial symptomatic effects led to further evaluation of IV iron. Intravenous iron therapy has evolved from the early inauspicious start. Intravenous iron is composed of two elements, the iron hydroxide core, which is surrounded by a protective carbohydrate shell (figure 2).7 The original IV iron’s carbohydate shell did not bind the iron well, resulting in the release of labile free iron, with associated toxicity, tarnishing the reputation of IV iron treatment.8 Subsequently, intramuscular iron was developed, but was unpopular with patients due to buttock staining, and the need for repeated painful injections.9
Parenteral treatment was developed with the introduction of high molecular weight (HMW) iron dextran, but these tarnished the safety reputation of IV iron due to the relatively high risk of anaphylaxis, and HMW iron dextran was removed in 2009.10 The development of recombinant erythropoetin spurred the development of modern iron formulations, such as low molecular weight iron dextran (e.g. Cosmofer®▼), which have relatively few side effects but do require dilution in a large volume, which potentially can be troublesome for heart failure patients. These have been used widely, and nowadays they may be substituted at pharmacy level due to cost for more modern irons, with relatively few side effects.11
Over time, improvements in the formulation of the carbohydrate shell slowed the release of free iron into the circulation, allowing larger doses of IV iron to be administered over shorter periods. For these modern IV iron formulations, each patient should be observed for adverse effects for at least 30 minutes following each administration. Facilities for cardio-respiratory resuscitation and equipment for handling acute anaphylactic/anaphylactoid reactions should be available. These modern irons have different pharmokinetic profiles (figure 3).12 Two common IV iron preparations in routine use are ferric carboxymaltose (Ferinject®▼, Vifor Pharma) and ferric derisomaltose (Monofer®▼, Pharmacosmos). (Editors’ note: ferric derisomaltose was formerly known as iron isomaltoside and the current name is used throught this article). Table 1 describes the differences between irons. Both have complex carbohydrate shells, without dextran and with a low immunogenic potential minimising risk of anaphylaxis. Ferric derisomaltose has a unique matrix structure limiting the release of free iron. Due to their unique formulations, particularly the pharmokinetic profile, different iron preparations cannot be regarded as bioequivalent, as their pharmocokinetic profiles are different. While high doses of both products may be administered over a short space of time, ferric derisomaltose allows for more iron (2 g rather than 1 g) to be given over 30 minutes, which is attractive in minimising patients attendance and maximising clinic efficiency.
Table 1. Characteristics of high-dose intravenous iron products available in the UK
| Active ingredient | Ferric carboxymaltose | Ferric derisomaltose | LMW iron dextran |
|---|---|---|---|
| Brand name | Ferinject® | Monofer® | Cosmofer® |
| Labile iron content (%) | 0.5 | 1 | 2 |
| Plasma terminal half life (h) | 7–12 | 24–96 | 20 |
| Max single iron dose (mg) | 1,000 | 20 mg/kg (500–2,000 mg) | 20 mg/kg |
| Minimum admin time | 15 mins | 15–30 mins | 4–6 hours |
| Key: LMW = low molecular weight Data from: Electronic Medicines Compendium (EMC). https://www.medicines.org.uk/emc/ |
|||
Efficacy and tolerability of iron
HF is associated with substantial morbidity and mortality, and as iron deficiency is fairly ubiquitous, treatment with iron is an attractive strategy. Trials of IV iron in patients with heart failure with reduced ejection fraction have shown an appealing improvement in symptoms.
Early small studies13 reported a significant symptomatic benefit from IV iron in HFrEF, leading to larger studies of IV ferric carboxymaltose (CONFIRM-HF, EFFECT-HF, FAIR-HF – table 2) with a variety of symptomatic outcome measures.5,6,14 As one might expect, these exploratory studies recruited relatively small numbers of participants (maximum 459), followed-up over a relatively short period of time, between six and 12 months, demonstrated that administration of IV iron treatment was associated with reduced symptomatic decline. Promisingly, hospitalisation for worsening HF, a secondary end point in the CONFIRM-HF study, were significantly reduced.15 Since these publications, international guidelines have encouraged the use of other HF treatments, such as cardiac resynchronisation therapy, which has become widely available, and subsequently, mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors have become standard therapy for a subset of HFrEF patients.
Table 2. Clinical trials of heart failure with reduced ejection fraction (HFrEF) patients treated with intravenous iron
| FAIR-HF4 | CONFIRM-HF5 | EFFECT-HF11 | |
|---|---|---|---|
| CHF patient population | NYHA II or III, LVEF ≤45%, Hb 9.5–14.5 g/dL | NYHA II or III, LVEF ≤45%, Hb <15 g/dL | NYHA II or III, LVEF ≤45%, Hb <15 g/dL |
| No. of participants | 459 | 301 | 172 |
| Iron | FCM | FCM | FCM |
| Duration (weeks) | 24 | 52 | 24 |
| Primary end point | PGA | 6MWT change | peak VO2 max change |
| Key: 6MWT = six-minute walk test; CHF = chronic heart failure; FCM = ferric carboxymaltose; Hb = haemoglobin; LVEF = left ventricular ejection fraction; NHYA = New York Heart Association class; Peak VO2 = peak oxygen consumption; PGA = patient global assessment | |||
Side effects of IV iron including hypophosphataemia
The safety profile of IV iron continues to influence clinicians’ decisions, particularly concern regarding serious allergic reactions. Widespread use of IV iron in dialysis patients using modern formulations have shown the incidence of serious adverse events is less than 1:200,000.16 The perception of danger from IV iron relates to two common adverse events: minor infusion reactions likely to be complement mediated and, in the past, a hypersensitivity reaction from pretreatment with diphernyhydramine. The former consists of mild myalgia or facial flushing, these abate without treatment, and plasma tryptase levels are normal, but concern arises due to the historical association of high dextran IV iron with anaphylaxis. Often infusions can re-commence after a minor reaction, usually administered at a slower rate.
It is postulated that theoretically free iron could potentially cause oxidative stress resulting in adverse cardiovascular events. Ferritin and transferrin sequestrate free iron, but it is conjectured that IV iron could saturate the proteins’ ability to bind iron, with poorly bound iron reacting with hydrogen peroxide (Fenton reaction) resulting in generation of hydoxyl radicals. Hydoxyl radicals are highly toxic, denaturing proteins, DNA and lipids – however, a study of dialysis patients did not find any greater risk of events compared with controls.17
Another concern is that IV iron could be associated with infections, yet prospective data suggest the opposite. Inferential reports link the two, but this allegation has been rejected by trials in both renal18 and HF patients.5
Hypophosphataemia is a relatively frequent occurrence following IV ferric carboxymaltose treament and this is a concern for HF patients, in contrast to renal failure patients who usually have excess serum phosphate. The explanation for the higher incidence of hypophosphataemia is that infusion of ferric carboxymaltose increases circulatory concentrations of biologically active fibroblast growth factor 23, which increases urinary phosphate excretion by reducing tubular phosphate re-absorption, with associated calcitroil deficiency and secondary hyperparathyroidism.19 Compared with ferric derisomaltose, the incidence of hypophosphataemia was significantly greater (75% vs. 8%). As symptoms of hypophosphataemia are non-specific they may be overlooked, as generalised weakness and fatigue are common complaints, and additionally, patients may be asymptomatic.20,21 There are inferential case reports of admissions with associated muscle pain and fractures due to osteomalacia in gastrointestinal patients, rather than renal patients who tend to have higher levels of serum phosphate, receiving repeated doses of ferric carboxymaltose, and the resulting hypophosphosphataemia may be treatment resistant.22 It is noted that hypophosphataemia can persist for up to two years (mean six months) after treatment with ferric carboxymaltose.23,24
Differences between products
Ideally, efficient administration of IV iron will minimise patient attendance and staff time. Hence, the dose of IV iron administered will impact on frequency of re-dosing depending on how many sessions are required to replenish the iron deficit. Prospective clinical trials have allayed concern about administering high doses of IV iron compared with low doses, with a notable safety profile in a dialysis-dependent population, which found a diminished risk of cardiovascular events in patients treated with high-dose iron.25
High doses of iron will correct iron deficiency in a single treatment if enough iron is administered.26 In a retrospective review of HFrEF, only 39% would receive enough iron treatment with the administration of 1 g as the average target dose was 1,308 ± 470 mg.27 Treatment to target dose was associated with a significant improvement in New York Heart Association (NYHA) class. Underdosing was associated with ongoing iron deficiency and less improvement in iron parameters. In addition, a dose deficit was associated with reduced symptomatic improvement.
Ongoing outcome studies and meta-analysis – hospitalisation and mortality will be reduced
Could IV iron effect hard outcomes? Post-hoc analysis of the CONFIRM-HF study supported the hypothesis that treatment with IV iron was associated with reduced hospitalisation. An individual patient data meta-analysis of 839 patients found IV iron treatment was associated with a significant reduction in the risk of HF hospitalisation and cardiovascular mortality (rate ratio 0.59, 95% confidence interval 0.4 to 0.88, p=0.009).15
Uncertainty remains about the long-term benefits of IV iron on cardiovascular outcomes, its safety and efficacy. Fortunately, ongoing clinical trials in symptomatic acute and chronic HFrEF patients with iron deficiency (table 3) powered to determine the effect on mortality and hospitalisation should provide an answer. The studies consist of three with ferric carboxymaltose and one with ferric derisomaltose allowing some comparison between the products.
Table 3. Ongoing clinical trials of intravenous iron in patients with heart failure examining morbidity and mortality
| AFFIRM-HF | FAIR-HF2 | HEART-FID | IRONMAN | |
|---|---|---|---|---|
| Clinicaltrials.gov registration number | NCT02937454 | NCT03036462 | NCT03037931 | NCT02642562 |
| CHF patient population | AHF, LVEF <50% | CHF | CHF (LVEF ≤35%, hospitalised within 12 months) | AHF and CHF – LVEF ≤45%, current or recent (6/12) hospitalisation or elevated naturetic peptides |
| Planned enrolment | 1,110 | 1,200 | 3,014 | 1,300 |
| Iron preparation | FCM | FCM | FCM | IIM |
| Duration | 52 weeks | at least 52 weeks | 52 weeks | Minimum 2.5 years following recruitment |
| Estimated completion date | July 2020 | December 2021 | January 2021 | Febuary 2021 |
| Primary end points | HF hospitalisation and CV death | Combined HF hospitalisation and CV death | HF hospitalisation and CV death | |
| Key: AFFIRM-AHF = Study to Compare Ferric Carboxymaltose with Placebo in Patients with Acute Heart Failure and Iron Deficiency; AHF = acute heart failure; CHF = chronic heart failure; CV = cardiovascular; FAIR-HF2 = Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality; FCM = ferric carboxymaltose; HEART-FID = Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure with Iron Deficiency; HF = heart failure; IIM = iron (ferric) derisomaltose; IRONMAN = Intravenous Iron Treatment in Patients with Heart Failure and Iron Deficiency; LVEF = left ventricular ejection fraction | ||||
In addition, we do not know whether total iron replenishment in one session should be favoured over more frequent smaller dose IV iron infusions. Lastly, should those patients re-develop iron deficiency, should they receive a top up dose and when should re-testing occur?
Conclusion
Iron deficiency appears to a propitious therapeutic target for patients with HFrEF, with auspicious symptomatic outcomes seen in initial studies. Longer-term clinical trials are exploring the effect on morbidity and mortality of IV iron treatment in iron deficient HFrEF patients.
Key messages
- Heart failure with reduced ejection fraction is associated with iron insufficiency. Intravenous iron is a safe and effective treatment
- Clinical studies reflecting the clinical outcomes of iron infusions in these patients will report in the near future
Conflicts of interest
PF has participated in an educational event for Pharmocosmos, advisory board for Pharmocosmos 2020, and is principle investigator in the BHF Ironman study. CI in study with equipment loaned by Medtronic. Investigator in studies for Medtronic, Abbott, Biotronik, Microport.
Paul Foley
Consultant Cardiologist
Wiltshire Cardiac Centre, The Great Western Hospital, Swindon, SN3 6BB
Articles in this supplement
Prevalence, causes, diagnosis and guidelines for treatment
United Kingdom treatment of iron deficiency in heart failure: are we missing opportunities?
Iron deficiency – the invisible comorbidity in HF: prioritising QoL as a target for treatment
References
1. von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure. JACC Heart Fail 2019;7:36–46. https://doi.org/10.1016/j.jchf.2018.07.015
2. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 2006;1763:690–9. https://doi.org/10.1016/j.bbamcr.2006.03.014
3. Lewis GD, Malhotra R, Hernandez AF et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 2017;317:1958–66. https://doi.org/10.1001/jama.2017.5427
4. Ambrosy AP, Lewis GD, Malhotra R et al. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. J Cardiovasc Med (Hagerstown) 2019;20:223–5. https://doi.org/10.2459/JCM.0000000000000736
5. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–48. https://doi.org/10.1056/NEJMoa0908355
6. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–68. https://doi.org/10.1093/eurheartj/ehu385
7. Von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure. JACC Heart Fail 2019;7:36–46. https://doi.org/10.1016/j.jchf.2018.07.015
8. Goetsch AT, Moore C, Minnich V. Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. Blood 1946;1:129–42. https://doi.org/10.1182/blood.V1.2.129.129
9. Baird IM, Podmore DA. Intramuscular iron therapy in iron-deficiency anaemia. Lancet 1954;267:942–6. https://doi.org/10.1016/S0140-6736(54)92555-6
10. Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964;23:354–8. https://doi.org/10.1182/blood.V23.3.354.354
11. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clinic Proc 2015;90:12–23. https://doi.org/10.1016/j.mayocp.2014.10.007
12. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3:12–33. https://doi.org/10.3390/pharmaceutics3010012
13. Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225–7. https://doi.org/10.1016/j.jacc.2006.07.015
14. van Veldhuisen DJ, Ponikowski P, van der Meer P et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017;136:1374–83. https://doi.org/10.1161/CIRCULATIONAHA.117.027497
15. Anker SD, Kirwan B-A, van Veldhuisen DJ et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125–33. https://doi.org/10.1002/ejhf.823
16. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378–82. https://doi.org/10.1093/ndt/gfi253
17. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 2004;15:1648–55. https://doi.org/10.1097/01.ASN.0000130149.18412.56
18. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014;12:296–300. https://doi.org/10.2450/2014.0094-14
19. Wolf M, Rubin J, Achebe M et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA 2020;323:432–43. https://doi.org/10.1001/jama.2019.22450
20. Glaspy JA, Lim-Watson MZ, Libre MA et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag 2020;16:245–59. https://doi.org/10.2147/TCRM.S243462
21. Fang W, Kenny R, Rizvi Q-A, McMahon LP, Garg M. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status. BMC Gastroenterol 2020;20:183. https://doi.org/10.1186/s12876-020-01298-9
22. Fang W, McMahon LP, Bloom S, Garg M. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open 2019;3:438–40. https://doi.org/10.1002/jgh3.12150
23. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 2018;3:e124486. https://doi.org/10.1172/jci.insight.124486
24. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015;2015:468675. https://doi.org/10.1155/2015/468675
25. Macdougall IC, White C, Anker SD et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2018;380:447–58. https://doi.org/10.1056/NEJMoa1810742
26. Frigstad SO, Haaber A, Bajor A et al. The NIMO Scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract 2017;2017:4585164. https://doi.org/10.1155/2017/4585164
27. Martens P, Minten L, Dupont M, Mullens W. The importance of dose optimisation in the treatment of iron deficiency in heart failure. Acta Cardiol 2019;1–5. https://doi.org/10.1080/00015385.2019.1625554
